Core Viewpoint - The approval of the clinical research plan for IMM0306 marks a significant advancement in innovative therapies for relapsed/refractory follicular lymphoma, leading to a notable increase in the company's stock price [1] Company Summary - 宜明昂科-B (01541) experienced a stock price increase of over 9%, currently trading at 7.31 HKD with a transaction volume of 10.70 million HKD [1] - The company has received approval from the National Medical Products Administration for the III phase clinical research plan of IMM0306 in combination with lenalidomide for treating relapsed/refractory follicular lymphoma [1] - IMM0306 is the world's first clinical-stage dual-targeting bispecific molecule targeting CD47 and CD20, designed to block the "don't eat me" signal, activating macrophages and NK cells [1] - The drug preferentially binds to CD20 rather than CD47, effectively eliminating malignant B cells while minimizing toxicity, thereby improving treatment outcomes [1] - The company holds global intellectual property and commercialization rights for IMM0306 [1]
宜明昂科-B午后涨超9% IMM0306的III期临床研究方案获CDE许可